DXCM · 10-Q · 2026Q3

DEXCOM INC

Filed 2026-10-29 · Healthcare · View original filing on EDGAR

Everything DXCM's SEC filings said, ranked

Ranked Events

• Operating Income and MarginsImportance 79 · Surprise 64
  Nine-month operating income rose $312.0 million, or approximately 53%, to $900.8 million from $588.8 million in 2025. Third-quarter operating income increased $84.7 million, or 35%, to $327.2 million. Nine-month net…
• Gross Margin DriversImportance 59 · Surprise 48
  Nine-month gross profit increased $435.5 million, from $2,009.2 million in 2025 to $2,444.7 million in 2026, and third-quarter gross profit increased $133.0 million to $864.4 million. Gross margin improved with higher…
• Capital Return ProgramImportance 58 · Surprise 82
  Net cash used in financing activities was $1,023.8 million for the nine months ended September 30, 2026, an $859.6 million increase from the prior-year period. The increase included $816.4 million more cash used to…
• Liquidity and Cash PositionImportance 42 · Surprise 14
  Cash, cash equivalents, and short-term marketable securities totaled $1.82 billion at September 30, 2026, down $180.8 million from $2.00 billion at December 31, 2025; $1.42 billion, or approximately 78%, was located in…
• Capital Expenditure OutlookImportance 34 · Surprise 42
  Dexcom expects significant capital expenditures over the next year for equipment and continued investment in manufacturing facilities. Long-term capital requirements also include development of manufacturing facilities…
• Product Launch and TransitionImportance 34 · Surprise 42
  Dexcom launched its G7 Continuous Glucose Monitoring System in 2023 and G7 15 Day in late 2025. Stelo, launched in the U.S. in August 2024, was the first over-the-counter glucose biosensor in the country and is…
• Revenue Performance and MixImportance 32 · Surprise 40
  Revenue for the three months ended September 30, 2026 rose 11% year over year to $1,344.5 million, while nine-month revenue increased 13% to $3,844.8 million. Nine-month U.S. revenue grew from $2,443.4 million to…
• Income Tax Rate ChangesImportance 30 · Surprise 40
  For the nine months ended September 30, 2026, income tax expense was $198.0 million, up $19.3 million from 2025, while the estimated annual effective tax rate declined to 21.7% from 22.5%. The lower rate primarily…
• Regulatory Approval MilestonesImportance 29 · Surprise 42
  In June 2026, the FDA cleared Stelo for use by children ages 2 years and older who do not use insulin. Stelo was launched in the United States in August 2024 as the first over-the-counter glucose biosensor for adults…
• Manufacturing and CapacityImportance 29 · Surprise 24
  Dexcom reported that improved manufacturing efficiencies, higher production volumes, and a more favorable manufacturing mix improved fixed-cost absorption in the first nine months of 2026. The company said demand…
• Operating Expense TrendsImportance 28 · Surprise 22
  Nine-month selling, general and administrative expense increased $114.5 million, or approximately 12%, to $1,084.0 million from $969.5 million. The increase included $47.9 million in advertising and marketing, $22.6…
• Geographic Market CommentaryImportance 26 · Surprise 40
  For the nine months ended September 30, 2026, U.S. revenue was $2,735.5 million, up from $2,443.4 million in the prior-year period, while international revenue was $1,109.3 million, up from $959.0 million. Both regions…
• Market Demand TrendsImportance 26 · Surprise 40
  Dexcom attributed revenue growth to increased disposable-sensor sales volume and continued growth of its worldwide customer base. The company added approximately 600,000 to 700,000 net customers, excluding Stelo…
• Strategic InitiativesImportance 20 · Surprise 24
  Dexcom plans to develop future generations of technologies focused on improved performance and convenience, including capabilities for intelligent insulin administration. Over the longer term, it plans to improve…
• Distribution ChannelsImportance 7 · Surprise 6
  Dexcom uses a direct sales organization in North America and certain international markets to reach health care professionals who can educate and influence CGM adoption. Distributor arrangements complement those direct…
• Debt and Liquidity PositionImportance 7 · Surprise 6
  Dexcom had outstanding senior convertible notes due in May 2028, with principal potentially convertible into cash and/or common shares before maturity if specified conditions are met. The company reported a…

Revenue by Geography (in millions)